HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis
出版年份 2019 全文链接
标题
HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis
作者
关键词
-
出版物
PHARMACOGENOMICS JOURNAL
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-08-06
DOI
10.1038/s41397-019-0092-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Association Between HLA genotypes and Oxcarbazepine-induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis
- (2018) Wimonchat Tangamornsuksan et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions
- (2018) Wimonchat Tangamornsuksan et al. JAMA Dermatology
- Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population
- (2018) Taisei Mushiroda et al. JAMA Neurology
- Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis
- (2018) Wimonchat Tangamornsuksan et al. PHARMACOGENOMICS JOURNAL
- Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity
- (2017) G. S. Ghattaoraya et al. International Journal of Immunogenetics
- Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes
- (2017) C F Spraggs et al. PHARMACOGENOMICS JOURNAL
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
- (2016) Martine Piccart-Gebhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials
- (2016) Yong Xin et al. Cancer Medicine
- Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis
- (2015) Wimonchat Tangamornsuksan et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01
- (2015) Makoto Hirasawa et al. PLoS One
- Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
- (2014) Yi Ling Teo et al. Expert Opinion on Drug Metabolism & Toxicology
- Prospective Validation ofHLA-DRB1*07:01Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
- (2014) Daniel J. Schaid et al. JOURNAL OF CLINICAL ONCOLOGY
- Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations
- (2014) Faviel F. González-Galarza et al. NUCLEIC ACIDS RESEARCH
- Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience
- (2013) Bulent Cetin et al. Breast Care
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
- (2013) Rashmi R. Shah et al. DRUG SAFETY
- Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
- (2013) Wimonchat Tangamornsuksan et al. JAMA Dermatology
- Lapatinib-Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes
- (2012) C F Spraggs et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
- (2012) Paul E Goss et al. LANCET ONCOLOGY
- Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
- (2011) Ratchadaporn Somkrua et al. BMC Medical Genetics
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer
- (2011) Colin F. Spraggs et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib-induced hepatitis: A case report
- (2011) Stavros Peroukides WORLD JOURNAL OF GASTROENTEROLOGY
- Lapatinib for breast cancer: a review of the current literature
- (2010) Robyn J MacFarlane et al. Expert Opinion On Drug Safety
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
- HLA-B*5701 Screening for Hypersensitivity to Abacavir
- (2008) Simon Mallal et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search